“We’re very excited about the addition of these well-respected sites to the first-rate hospitals already participating in the IBV Valve Trial,” said Rick Shea, president and CEO, Spiration. “The approximately 30 sites actively enrolling patients in the study are leaders in their communities helping to advance medical research that may one day improve the lives of people with emphysema, a debilitating condition that severely impacts quality of life.”
